Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis
Lutetium Lu 177 vipivotide tetraxetan is a radioligand that pairs the beta-emitting radionuclide lutetium-177 with a PSMA-binding ligand. It binds PSMA-expressing cells, where beta radiation damages DNA and kills the cells, including nearby cells. It is studied in metastatic castration-resistant and other prostate cancers.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06894511 | Phase 2 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Active not recruiting | NVS |
| NCT06943495 | Phase 1 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Prostate CancerProstate Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →